Conditions: Functional Abdominal Pain
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 4
Healthy volunteers: no

Brief summary:
The investigators hypothesize that using Cyproheptadine in a placebo-controlled crossover trial would help relieve abdominal pain associated with (Functional Abdominal Pain (FAP) in children, achieving a greater response than that observed with placebo. In addition to assessing self-report of pain and other symptoms, the investigators also propose to perform experimental somatic pain testing to determine if there is evidence of peripherally-maintained central sensitization in children with FAP. The investigators also hypothesize that there will be an increase in somatic pain threshold after completion of a Cyproheptadine course compared to baseline testing prior to treatment, and compared to placebo. This would allow children with FAP to return to normal function, improve symptoms and overall general well-being

Detailed description:

Arms:
arm 1: 4 weeks of cyproheptadine or placebo with crossover to the other arm 2: 4 weeks of cyproheptadine or placebo with crossover to the other

Interventions: intervention 1: Cyproheptadine intervention 2: sugar pill
Intervention descriptions: intervention 1: 4 weeks of cyproheptadine or placebo with crossover to the other intervention 2: 4 weeks of cyproheptadine or placebo with crossover to the other

Protocol document: